Table 1.

Common genetic variants that are associated with risk of cancer therapy-induced cardiotoxicity

Proposed mechanism	Gene	Reference SNP ID	Odds ratio	p-value
Drug transport	ABCB1	rs1045642 [34]	0.48	0.049
	ABCB4	rs1149222 [33]	1.87	0.005
	ABCC1	rs246221 [30]	1.59	0.02
		rs4148350 [33]	3.44	0.001
	ABCC2	rs8187694 [31]	2.3	0.049
		rs8187710 [32]	4.33	< 0.01
	SLC10A2	rs9514091 [33]	0.43	0.003
	SLC28A3	rs4877847 [33]	0.60	0.009
		rs7853758 [33]	0.31	1.0 x 10e-4
	SLC22A7	rs4149178 [36]	0.45	0.001
	SLC22A17	rs4982753 [36]	0.50	4.4 x 10e-4
Drug metabolism	CBR3	rs1056892 [39]	3.3 (G/G genotype)	0.006 (G/G genotype)
Oxidative stress response	HAS3	rs2232228 [42]	5.2 (G/A genotype) 9.9 (A/A genotype)	0.007 (G/A genotype) 0.002 (A/A genotype)
	GSTM1	N/A (Homozygous deletion) [44]	2.7	0.007
Iron metabolism	HFE	rs1799945 [51]	3.44	0.005
Topoisomerase-mediated DNA damage	RARG	rs2229774 [57]	4.7	5.9 x 10e-8
Splicing of a sarcomere gene	CELF4	rs1786814 [60]	2.3	0.006